| Oxford
BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of novel gene-based therapeutics with a
focus on the areas of oncology and neurotherapy.
The Company was established in 1995 as a
spin out from Oxford University, and is
listed on the London Stock Exchange.
In
addition to its technical expertise in gene
delivery, Oxford BioMedica has in-house
clinical, regulatory and manufacturing know-how.
The development pipeline includes two novel
anti-cancer products in clinical trials;
two neurotherapy products in advanced preclinical
development for Parkinson’s disease
and retinopathy; and three further preclinical
neurotherapy products. The Company is underpinned
by an extensive preclinical and research
portfolio and over 80 patent families, which
represents one of the broadest patent estates
in the field.
The
Company has established a neurotherapy pipeline
of product candidates based on its LentiVector
technology, which includes ProSavin®
for Parkinson’s disease, RetinoStat®
for retinopathy, MoNuDin® for motor
neuron disease, SMN1-G for spinal muscular
atrophy and Innurex® for nerve repair.
Current licencees of the LentiVector technology
for drug discovery and transgenic applications
include Merck & Co and Viragen. |
